Biopharmaceutical Contract Manufacturing Market Set for Nearly 3X Growth by 2029, with Increased Adoption of Monoclonal Antibodies for Chronic Diseases

Jan 23,2020 | Healthcare, Pharmaceuticals and Medical devices

Reduced overall time to market investment in new drugs, access to expensive technologies, and greater flexibility are some advantages offered by biopharmaceutical manufacturing companies. On the back of these factors, several large companies have outsourced their biopharmaceutical manufacturing operations. Biopharmaceutical contract manufacturing is highly preferred among biopharmaceutical companies with limited in-house production capacity. Pharmaceutical companies mainly focus on core areas of competence, and hence, do not prefer to take financial risks in the event of formulating the final dose of medicines. This is anticipated to accelerate the growth of the global biopharmaceutical contract manufacturing market during forecast period, estimated to be valued at US$ 17 Bn by 2029.

Key Takeaways of Biopharmaceutical Contract Manufacturing Market Study

  • Although microbial-based platforms are abundantly used for the production of pharmaceuticals, mammalian-based cell culture is expected to gain traction during the forecast period, owing to higher efficiency and increasing demand.
  • In terms of product type, monoclonal antibodies currently hold a larger share of the biopharmaceutical contract manufacturing market, due to their superior efficacy as well as increasing adoption for the treatment of chronic diseases.
  • North America is anticipated to be the most lucrative region in the global biopharmaceutical contract manufacturing market, offering growth opportunities to market players.
  • The commercial application of biopharmaceutical contract manufacturing is expected to contribute a higher share as compared to clinical application by the end of 2029.

“Asia Pacific is gaining attention among manufacturers for biologics production at reduced manufacturing cost. Emerging regions offering greater profit margins are major focus points for biopharmaceutical contract manufacturing, globally.”

biopharmaceutical contract manufacturing market share by region

Competitive Landscape of Biopharmaceutical Contract Manufacturing Market

For More Detailed Insights on Biopharmaceutical Contract Manufacturing Market

Key players in the biopharmaceutical contract manufacturing market are now focusing on geographic expansion through mergers and acquisitions. In October, 2017, Catalent Inc. acquired Catalent Indiana, earlier called Cook Pharmacia, LLC., which was an integrated provider of drug products and drug substance and related services. Further, leading players in the biopharmaceutical contract manufacturing market are also involved in different industrial developmental activities to expand their service offerings. For instance, in 2016, Sandoz International GmbH entered into an agreement with Kyowa Hakko Kirin Co., Ltd. for the promotion and distribution of its monoclonal antibody biosimilar - Rituximab, in Japan.

What else is in the report?

Future market insights offers a unique perspective and actionable insights on the biopharmaceutical contract manufacturing market in its latest study, presenting historical demand assessment from 2014-2018 and projections for 2019-2029, based on platform (mammalian-based and microbial-based), product type (monoclonal antibodies, recombinant proteins, vaccines, insulin, interferon, growth factors, and others), application (clinical and commercial), and therapeutic area (autoimmune diseases, oncology, metabolic diseases, opthalmology, cardiovascular diseases, infectious diseases, neurology, respiratory disorders, and others), across seven key regions.

For additional information, write to the analyst at

About Healthcare division of FMI

The Healthcare team at Future Market Insights has consistently tracked and analyzed rapidly evolving trends and developments in the global healthcare industry, encompassing pharmaceuticals and medical devices markets. The team facilitates corporates, government, investors, and associated audiences in the healthcare sector to identify and accentuate vital aspects applicable to product strategy, regulatory landscape, technology evolution, and other crucial issues to achieve sustainable success. Our unique approach to gathering market intelligence equips you in devising innovation-driven trajectories for your business. Know more about our sector coverage.

About Future Market Insights (FMI)

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centres in the U.S. and India. FMI's latest market research reports and industry analysis help businesses navigate challenges and take critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously track emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Media Contact

Rahul Pandita

Rahul Pandita

Head – Corporate Communications

Abhishek Budholiya

Abhishek Budholiya

Head – Digital Marketing